Ontology type: schema:ScholarlyArticle Open Access: True
2021-08-09
AUTHORSShaheenah Dawood, Maria Konstantionva, Rebecca Dent, Florencia Perazzo, Sung-Bae Kim, Cynthia Villarreal-Garza, Sandra Franco, Ming-Shen Dai, Sergio Simon
ABSTRACTPurposeThe therapeutic landscape of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (mBC) has evolved considerably with the introduction of newer targeted agents and their combinations with endocrine therapies. In this scenario, optimizing treatment selection and sequencing is daunting for clinicians. The purpose of this review is to provide evidence-based answers to key clinical questions on treatment selection and sequencing for the management of HR + HER2 − mBC.DesignA panel of nine key opinion leaders from Argentina, Brazil, Colombia, Mexico, Moscow, Singapore, South Korea, Taiwan, and UAE convened in October 2018. They reviewed the literature and formulated answers to clinical questions on optimizing the management of HR + HER2 − mBC.ResultsEvidence-based answers were formulated for: (1) optimal initial treatment choice; (2) ovarian function suppression, optimal endocrine partner, and role of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors (in premenopausal women); (3) better first-line standard of care than aromatase inhibitors; (4) preferred second-line treatment; (5) treatment of oligometastatic disease; (6) factors influencing first-line single-agent endocrine therapy choice; (7) influence of endocrine resistance on treatment selection; (8) optimal maintenance regimen in visceral crisis; and (9) need for a breast cancer registry for patients with HR + HER2 − mBC. The panel also proposed a treatment-sequencing algorithm for the management of HR + HER2 − mBC.ConclusionThe current article will serve as a comprehensive guide for optimizing the management of HR + HER2 − mBC. The proposed breast cancer registry will help identify unmet needs and develop strategic regional policies to help improve access to optimized care for HR + HER2 − mBC. More... »
PAGES15
http://scigraph.springernature.com/pub.10.1186/s12919-021-00224-5
DOIhttp://dx.doi.org/10.1186/s12919-021-00224-5
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1140286771
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/34372853
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Oncology and Carcinogenesis",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Dubai Health Care City, Consultant Medical Oncologist, Mediclinic City Hospital - North Wing, Dubai, UAE",
"id": "http://www.grid.ac/institutes/grid.459770.8",
"name": [
"Dubai Health Care City, Consultant Medical Oncologist, Mediclinic City Hospital - North Wing, Dubai, UAE"
],
"type": "Organization"
},
"familyName": "Dawood",
"givenName": "Shaheenah",
"id": "sg:person.0771637610.47",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0771637610.47"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Head of the Department of antitumor drug therapy, F. VladimirskIy Moscow Regional Research Clinical Institute (MONIKI), Moscow, Russia",
"id": "http://www.grid.ac/institutes/grid.467082.f",
"name": [
"Head of the Department of antitumor drug therapy, F. VladimirskIy Moscow Regional Research Clinical Institute (MONIKI), Moscow, Russia"
],
"type": "Organization"
},
"familyName": "Konstantionva",
"givenName": "Maria",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Head, Breast Medical Oncology Team, National Cancer Center Singapore, Singapore, Singapore",
"id": "http://www.grid.ac/institutes/grid.410724.4",
"name": [
"Head, Breast Medical Oncology Team, National Cancer Center Singapore, Singapore, Singapore"
],
"type": "Organization"
},
"familyName": "Dent",
"givenName": "Rebecca",
"id": "sg:person.01361171050.45",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01361171050.45"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Oncology, Centro de Educaci\u00f3n M\u00e9dicae Investigaciones Cl\u00ednicas (CEMIC), Ciudad de Buenos Aires, Argentina",
"id": "http://www.grid.ac/institutes/grid.418248.3",
"name": [
"Department of Oncology, Centro de Educaci\u00f3n M\u00e9dicae Investigaciones Cl\u00ednicas (CEMIC), Ciudad de Buenos Aires, Argentina"
],
"type": "Organization"
},
"familyName": "Perazzo",
"givenName": "Florencia",
"id": "sg:person.01057754421.80",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01057754421.80"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Songpa-gu, Seoul, South Korea",
"id": "http://www.grid.ac/institutes/grid.413967.e",
"name": [
"Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Songpa-gu, Seoul, South Korea"
],
"type": "Organization"
},
"familyName": "Kim",
"givenName": "Sung-Bae",
"id": "sg:person.015757640033.05",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015757640033.05"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Depto. de Investigacion, Instituto Nacional de Cancerologia, Mexico city, Mexico",
"id": "http://www.grid.ac/institutes/grid.419167.c",
"name": [
"Centro de Cancer de Mama, Hospital Zambrano Hellion, Tecnologico de Monterrey, San Pedro Garza Garc\u00eda, NL, Mexico",
"Depto. de Investigacion, Instituto Nacional de Cancerologia, Mexico city, Mexico"
],
"type": "Organization"
},
"familyName": "Villarreal-Garza",
"givenName": "Cynthia",
"id": "sg:person.01057225306.39",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01057225306.39"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Head of Oncology, Cl\u00ednica del Country, Bogot\u00e1, Colombia",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Head of Oncology, Cl\u00ednica del Country, Bogot\u00e1, Colombia"
],
"type": "Organization"
},
"familyName": "Franco",
"givenName": "Sandra",
"id": "sg:person.010052147233.95",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010052147233.95"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Hematology/Oncology, Tri-Service General Hospital, National Defense Medical Center, Taipei City, Taiwan",
"id": "http://www.grid.ac/institutes/grid.278244.f",
"name": [
"Department of Hematology/Oncology, Tri-Service General Hospital, National Defense Medical Center, Taipei City, Taiwan"
],
"type": "Organization"
},
"familyName": "Dai",
"givenName": "Ming-Shen",
"id": "sg:person.0751031116.18",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0751031116.18"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Centro Paulista de Oncologia (CPO), Sao Paulo, Brazil",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Centro Paulista de Oncologia (CPO), Sao Paulo, Brazil"
],
"type": "Organization"
},
"familyName": "Simon",
"givenName": "Sergio",
"id": "sg:person.014520232162.61",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014520232162.61"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1007/s10549-018-05125-4",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1111320245",
"https://doi.org/10.1007/s10549-018-05125-4"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s12282-018-0838-8",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1101057009",
"https://doi.org/10.1007/s12282-018-0838-8"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1186/s12885-020-06933-y",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1127579844",
"https://doi.org/10.1186/s12885-020-06933-y"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/s41523-018-0094-2",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1110537179",
"https://doi.org/10.1038/s41523-018-0094-2"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s12325-013-0060-1",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1016141409",
"https://doi.org/10.1007/s12325-013-0060-1"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/s41523-018-0097-z",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1111375485",
"https://doi.org/10.1038/s41523-018-0097-z"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1186/s12916-019-1326-5",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1114002245",
"https://doi.org/10.1186/s12916-019-1326-5"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1186/s13045-018-0620-6",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1104512198",
"https://doi.org/10.1186/s13045-018-0620-6"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s10549-018-4867-y",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1105296572",
"https://doi.org/10.1007/s10549-018-4867-y"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s12282-012-0430-6",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1032224793",
"https://doi.org/10.1007/s12282-012-0430-6"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s10549-017-4523-y",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1092334133",
"https://doi.org/10.1007/s10549-017-4523-y"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s10549-017-4518-8",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1092841000",
"https://doi.org/10.1007/s10549-017-4518-8"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s10549-013-2814-5",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1041934981",
"https://doi.org/10.1007/s10549-013-2814-5"
],
"type": "CreativeWork"
}
],
"datePublished": "2021-08-09",
"datePublishedReg": "2021-08-09",
"description": "PurposeThe therapeutic landscape of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2\u2212) metastatic breast cancer (mBC) has evolved considerably with the introduction of newer targeted agents and their combinations with endocrine therapies. In this scenario, optimizing treatment selection and sequencing is daunting for clinicians. The purpose of this review is to provide evidence-based answers to key clinical questions on treatment selection and sequencing for the management of HR\u2009+\u2009HER2\u2009\u2212\u2009mBC.DesignA panel of nine key opinion leaders from Argentina, Brazil, Colombia, Mexico, Moscow, Singapore, South Korea, Taiwan, and UAE convened in October 2018. They reviewed the literature and formulated answers to clinical questions on optimizing the management of HR\u2009+\u2009HER2\u2009\u2212\u2009mBC.ResultsEvidence-based answers were formulated for: (1) optimal initial treatment choice; (2) ovarian function suppression, optimal endocrine partner, and role of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors (in premenopausal women); (3) better first-line standard of care than aromatase inhibitors; (4) preferred second-line treatment; (5) treatment of oligometastatic disease; (6) factors influencing first-line single-agent endocrine therapy choice; (7) influence of endocrine resistance on treatment selection; (8) optimal maintenance regimen in visceral crisis; and (9) need for a breast cancer registry for patients with HR\u2009+\u2009HER2\u2009\u2212\u2009mBC. The panel also proposed a treatment-sequencing algorithm for the management of HR\u2009+\u2009HER2\u2009\u2212\u2009mBC.ConclusionThe current article will serve as a comprehensive guide for optimizing the management of HR\u2009+\u2009HER2\u2009\u2212\u2009mBC. The proposed breast cancer registry will help identify unmet needs and develop strategic regional policies to help improve access to optimized care for HR\u2009+\u2009HER2\u2009\u2212\u2009mBC.",
"genre": "article",
"id": "sg:pub.10.1186/s12919-021-00224-5",
"inLanguage": "en",
"isAccessibleForFree": true,
"isPartOf": [
{
"id": "sg:journal.1039047",
"issn": [
"1753-6561"
],
"name": "BMC Proceedings",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "Suppl 10",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "15"
}
],
"keywords": [
"metastatic breast cancer",
"Breast Cancer Registry",
"treatment selection",
"Cancer Registry",
"clinical questions",
"cyclin-dependent kinase 4/6 inhibitors",
"human epidermal growth factor receptor",
"ovarian function suppression",
"optimal maintenance regimen",
"first-line standard",
"second-line treatment",
"initial treatment choice",
"key clinical questions",
"epidermal growth factor receptor",
"evidence-based answers",
"growth factor receptor",
"visceral crisis",
"advanced breast",
"endocrine therapy",
"oligometastatic disease",
"maintenance regimen",
"endocrine resistance",
"optimized care",
"HR positive",
"treatment choice",
"aromatase inhibitors",
"therapy choice",
"breast cancer",
"management of HR",
"unmet need",
"HER2",
"therapeutic landscape",
"factor receptor",
"key opinion leaders",
"registry",
"hr",
"expert group meeting",
"care",
"treatment",
"inhibitors",
"group meetings",
"management",
"regimen",
"patients",
"therapy",
"cancer",
"clinicians",
"breast",
"ResultsEvidence",
"disease",
"hormone",
"receptors",
"opinion leaders",
"sequencing",
"review",
"panel",
"current article",
"suppression",
"agents",
"factors",
"comprehensive guide",
"role",
"South Korea",
"choice",
"resistance",
"Taiwan",
"meeting",
"need",
"combination",
"selection",
"purpose",
"partners",
"literature",
"access",
"questions",
"guide",
"standards",
"Singapore",
"Korea",
"Brazil",
"answers",
"introduction",
"decisions",
"Colombia",
"UAE",
"article",
"influence",
"Mexico",
"crisis",
"Argentina",
"policy",
"leaders",
"Moscow",
"scenarios",
"landscape",
"sequencing decisions",
"algorithm",
"regional policy"
],
"name": "Optimizing treatment selection, and sequencing decisions for Management of HR-Positive, HER2-Negative advanced breast cancer \u2013 Proceedings from breast cancer expert group meeting",
"pagination": "15",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1140286771"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1186/s12919-021-00224-5"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"34372853"
]
}
],
"sameAs": [
"https://doi.org/10.1186/s12919-021-00224-5",
"https://app.dimensions.ai/details/publication/pub.1140286771"
],
"sdDataset": "articles",
"sdDatePublished": "2022-06-01T22:25",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220601/entities/gbq_results/article/article_923.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1186/s12919-021-00224-5"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12919-021-00224-5'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12919-021-00224-5'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12919-021-00224-5'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12919-021-00224-5'
This table displays all metadata directly associated to this object as RDF triples.
290 TRIPLES
22 PREDICATES
136 URIs
115 LITERALS
7 BLANK NODES